ACTOS SHOWN TO REDUCE RISK OF SECONDARY STROKE IN DIABETES PATIENTS

Japanese drugmaker Takeda has announced results of new studies that show Actos (pioglitazone HCl), an oral antidiabetic medication, significantly reduced the risk of recurrent stroke in high-risk patients with Type 2 diabetes.

These new analyses from the PROactive study, which involved 5,238 patients with Type 2 diabetes and macrovascular disease, examined the effects of Actos on the risk of stroke and other cardiovascular outcomes in high-risk patients with and without prior stroke. Pre-specified study endpoints included all-stroke and cardiovascular disease death, myocardial infarction or stroke.

According to the results, there were statistically significant benefits of Actos in patients who had suffered a prior stroke. The incidence of recurrent stroke was reduced by 47 percent and the combined risk of death, myocardial infarction or stroke was reduced by 28 percent. There was no effect of Actos on subsequent strokes in patients who had never experienced a stroke.